Acetylcholinesterase inhibitors and cholinergic modulation in Myasthenia Gravis and neuroinflammation

被引：34

作者：

Brenner, Talma ^{[1
,2
,3
]}

Nizri, Eran ^{[1
,2
,3
]}

Irony-Tur-Sinai, Michal ^{[1
,2
,3
]}

Hamra-Amitay, Yasmine ^{[1
,2
,3
]}

Wirguin, Itzhak ^{[4
]}

机构：

[1] Hadassah Univ Hosp, Dept Neurol, Lab Neuroimmunol, IL-91120 Jerusalem, Israel

[2] Hadassah Univ Hosp, Agnes Ginges Ctr Human Neurogenet, IL-91120 Jerusalem, Israel

[3] Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91010 Jerusalem, Israel

[4] Ben Gurion Univ Negev, Soroka Univ Med Ctr, Dept Neurol, IL-84105 Beer Sheva, Israel

来源：

JOURNAL OF NEUROIMMUNOLOGY | 2008年 / 201卷

关键词：

Acetylcholinesterase inhibitors; Myasthenia Gravis; Alzheimer's disease; Multiple Sclerosis; alpha-7-Acetylcholine receptors; Inflammation;

D O I：

10.1016/j.jneuroim.2008.05.022

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The cholinergic network affects various cellular functions including neurotransmission, and immune reactions. In Myasthenia Gravis (MG), diagnosis and symptomatic therapy are based on cholinergic modulation by acetylcholinesterase inhibitors (AChEI). In Alzheimer's disease (AD) a neurodegenerative disorder associated with inflammatory pathology, cholinergic systems cell loss occurs early. Treatments with special AChEI enhance cholmergic transmission and may act as anti-inflammatory agent via immunocompetent cells expressing alpha-7 acetylcholine receptor (AChR). In Multiple Sclerosis (MS) an inflammatory T-cell-mediated disease, demyelination and neurodegeneration follow neuroinflammation. MS treatment includes anti-inflammatory and immunomodulatory drugs. AChEI can induce cholinergic up-regulation with subsequent effect on neuroinflammation via alpha-7-AChR expressing cells. These effects are additional to the cognitive benefit induced by AChEl. (C) 2008 Elsevier B.V All rights reserved.

引用

页码：121 / 127

页数：7

共 58 条

[51] Multiple sclerosis: a two-stage disease [J].

Steinman, L .

NATURE IMMUNOLOGY, 2001, 2 (09) :762-764

[52] How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis [J].

Steinman, Lawrence ;

Zamvil, Scott S. .

ANNALS OF NEUROLOGY, 2006, 60 (01) :12-21

[53] Add-on therapy with acetylcholinesterase inhibitors for memory dysfunction in schizophrenia: A systematic quantitative review, part 2 [J].

Stip, Emmanuel ;

Sepehry, Amir Ali ;

Chouinard, Sylvie .

CLINICAL NEUROPHARMACOLOGY, 2007, 30 (04) :218-229

[54] Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing! [J].

Tabet, N. .

AGE AND AGEING, 2006, 35 (04) :336-338

[55] Alzheimer's disease is associated with a selective increase in α7 nicotinic acetylcholine receptor immunoreactivity in astrocytes [J].

Teaktong, T ;

Graham, A ;

Court, J ;

Perry, R ;

Jaros, E ;

Johnson, M ;

Hall, R ;

Perry, E .

GLIA, 2003, 41 (02) :207-211

[56] Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation [J].

Wang, H ;

Yu, M ;

Ochani, M ;

Amella, CA ;

Tanovic, M ;

Susarla, S ;

Li, JH ;

Wang, HC ;

Yang, H ;

Ulloa, L ;

Al-Abed, Y ;

Czura, CJ ;

Tracey, KJ .

NATURE, 2003, 421 (6921) :384-388

[57] Inflammation in neurodegenerative disease - A double-edged sword [J].

Wyss-Coray, T ;

Mucke, L .

NEURON, 2002, 35 (03) :419-432

[58] Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice [J].

Wyss-Coray, T ;

Yan, FR ;

Lin, AHT ;

Lambris, JD ;

Alexander, JJ ;

Quigg, RJ ;

Masliah, E .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (16) :10837-10842

← 1 2 3 4 5 6 →